Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 4:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 304 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: insulin glargine Clear all
Completed Phase 3 Interventional

A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.

NCT00755287
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
insulin glargine, metformin, taspoglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,072 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
74
States / cities
Phoenix, Arizona • Searcy, Arkansas • Concord, California + 63 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2016 · Synced Oct 29, 2026, 4:35 AM EDT
Completed Phase 3 Interventional

Insulin Glargine Vs Standard Insulin Therapy

NCT00222521
View directory record Official record
Conditions
Cystic Fibrosis Related Diabetes
Interventions
Glargine insulin
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 22, 2005 · Synced Oct 29, 2026, 4:35 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes

NCT06419777
View directory record Official record
Conditions
Gestational Diabetes, Pregnancy Related
Interventions
Insulin
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
430 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Rochester, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 29, 2026, 4:35 AM EDT
Completed Phase 3 Interventional Results available

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications

NCT02320721
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin Glargine (HOE901 - U300), Insulin Glargine (HOE901 - U100), Background therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
65 Years and older
Enrollment
1,014 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
64
States / cities
Saraland, Alabama • Fresno, California • Greenbrae, California + 57 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Oct 29, 2026, 4:35 AM EDT
Completed Phase 4 Interventional Results available

A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study

NCT03687827
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin degludec, Insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
498 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
34
States / cities
Chandler, Arizona • Tucson, Arizona • Fresno, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 29, 2026, 4:35 AM EDT
Completed Phase 3 Interventional

Afrezza® INHALE-1 Study in Pediatrics

NCT04974528
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Afrezza, Rapid-acting Insulin Analog, Basal Insulin
Biological
Lead sponsor
Mannkind Corporation
Industry
Eligibility
4 Years to 17 Years
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
39
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 29, 2026, 4:35 AM EDT
Completed Phase 3 Interventional Results available

Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes

NCT00972283
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, insulin glargine, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,006 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
66
States / cities
Alexander City, Alabama • Birmingham, Alabama • Goodyear, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Oct 29, 2026, 4:35 AM EDT
Terminated Phase 4 Interventional Results available

Insulin Glargine Versus Twice-Daily NPH

NCT00687453
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine at bedtime instead of NPH, NPH twice-daily
Drug
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 29, 2026, 4:35 AM EDT
Completed Early Phase 1 Interventional

Validation of Insulin Protocol for Glucocorticoid-induced Hyperglycemia in Diabetic Oncology Patients

NCT02012465
View directory record Official record
Conditions
Lymphoma, Diabetes Mellitus, Type 2, Hyperglycemia
Interventions
Insulin protocol
Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Oct 29, 2026, 4:35 AM EDT
Completed Phase 2 Interventional Results available

A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before

NCT03951805
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Insulin Glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
12
States / cities
Anaheim, California • Lancaster, California • Roswell, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Oct 29, 2026, 4:35 AM EDT
Completed Phase 4 Interventional

A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and Lantus

NCT00367445
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Inhaled Human Insulin (Exubera), Insulin Glargine (Lantus)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2008 · Synced Oct 29, 2026, 4:35 AM EDT
Completed Phase 4 Interventional Results available

Liraglutide Hospital Discharge Trial

NCT01919489
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Liraglutide + OADs, Glargine + OADs
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
5
States / cities
Miami, Florida • Atlanta, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 29, 2026, 4:35 AM EDT
Recruiting Phase 4 Interventional

Once-Daily vs Twice-Daily Insulin Glargine in Pregestational Diabetes Management

NCT07224893
View directory record Official record
Conditions
Pregestational Diabetes, Pregnancy
Interventions
Use of insulin glargine once daily, Use of insulin glargine twice daily
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 29, 2026, 4:35 AM EDT
Completed Phase 4 Interventional Results available

Insulin Glargine "All to Target" Trial

NCT00384085
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Glulisine, Insulin Glargine, Premixed Insulin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
30 Years to 80 Years
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 6, 2011 · Synced Oct 29, 2026, 4:35 AM EDT
Completed Phase 3 Interventional

Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin

NCT00135096
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
insulin glulisine, insulin glargine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 11, 2011 · Synced Oct 29, 2026, 4:35 AM EDT
Completed Phase 3 Interventional Results available

6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes

NCT00993473
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin glargine (HOE901), Neutral Protamine Hagedorn (NPH) insulin, Insulin lispro
Drug
Lead sponsor
Sanofi
Industry
Eligibility
1 Year to 6 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
Sacramento, California • San Diego, California • Greenwood Village, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2012 · Synced Oct 29, 2026, 4:35 AM EDT
Completed Phase 3 Interventional

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)

NCT05013229
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
IcoSema, Insulin glargine, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
66
States / cities
Guntersville, Alabama • Fresno, California • La Jolla, California + 59 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 29, 2026, 4:35 AM EDT
Completed Phase 4 Interventional Results available

Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery

NCT02556918
View directory record Official record
Conditions
Hyperglycemia
Interventions
Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Oct 29, 2026, 4:35 AM EDT
Completed Phase 2 Interventional Results available

Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes

NCT00612040
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin degludec, insulin glargine, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
9
States / cities
Walnut Creek, California • Honolulu, Hawaii • Idaho Falls, Idaho + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 29, 2026, 4:35 AM EDT
Completed Phase 2 Interventional Results available

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus

NCT01194258
View directory record Official record
Conditions
Diabetes Mellitus, Type II
Interventions
Insulin lispro, Insulin aspart, Recombinant human hyaluronidase PH20, Insulin glulisine, Insulin glargine
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
22
States / cities
Concord, California • Encino, California • Escondido, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Oct 29, 2026, 4:35 AM EDT
Completed Phase 4 Interventional Results available

Basal Insulin in the Management of Patients With Diabetic Ketoacidosis (DKA)

NCT00590044
View directory record Official record
Conditions
Diabetic Ketoacidosis
Interventions
insulin glargine+ glulisine, NPH + Regular insulin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Atlanta, Georgia • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Oct 29, 2026, 4:35 AM EDT
Completed Phase 3 Interventional Results available

A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes

NCT03214380
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
LY900014, Insulin Lispro, Insulin Glargine, Insulin Degludec, Metformin, SGLT2 inhibitor
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
933 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
32
States / cities
Fresno, California • La Mesa, California • Lancaster, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2020 · Synced Oct 29, 2026, 4:35 AM EDT
Completed Phase 1 Interventional

Effectiveness of Adding Subcutaneous Long-acting Glargine to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy

NCT01153100
View directory record Official record
Conditions
Diabetes
Interventions
Glargine
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
19 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 29, 2026, 4:35 AM EDT
Completed Not applicable Interventional Results available

Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin Glargine

NCT01089569
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Exenatide, Insulin Glargine
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 29, 2026, 4:35 AM EDT